Trial · NCT03398148
Participant flow180
How many started, completed or left each group, period by period.
1 to 20 of 180
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Substudy 1 Period 1 | STARTED | Substudy 1, Induction Period 1: Double-blind Placebo IV | 60 | |
| Substudy 1 Period 1 | STARTED | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | 61 | |
| Substudy 1 Period 1 | STARTED | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | 61 | |
| Substudy 1 Period 1 | STARTED | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | 58 | |
| Substudy 1 Period 1 | STARTED | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | 341 | |
| Substudy 1 Period 1 | STARTED | Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC | 0 | |
| Substudy 1 Period 1 | STARTED | Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC | 0 | |
| Substudy 1 Period 1 | STARTED | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV | 0 | |
| Substudy 1 Period 1 | STARTED | Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo | 0 | |
| Substudy 1 Period 1 | STARTED | Substudy 2, Induction Period 1: Double-blind Placebo IV | 0 | |
| Substudy 1 Period 1 | STARTED | Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV | 0 | |
| Substudy 1 Period 1 | STARTED | Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC | 0 | |
| Substudy 1 Period 1 | STARTED | Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC | 0 | |
| Substudy 1 Period 1 | STARTED | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV | 0 | |
| Substudy 1 Period 1 | STARTED | Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo | 0 | |
| Substudy 1 Period 1 | COMPLETED | Substudy 1, Induction Period 1: Double-blind Placebo IV | 53 | |
| Substudy 1 Period 1 | COMPLETED | Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV | 55 | |
| Substudy 1 Period 1 | COMPLETED | Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV | 58 | |
| Substudy 1 Period 1 | COMPLETED | Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV | 57 | |
| Substudy 1 Period 1 | COMPLETED | Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV | 306 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03398148/flow